Inhibiting intracellular signalling as a strategy for cancer chemoprevention

European Journal of Cancer

Volumn 30, Issue 8, 1994, Pages 1138-1144

  Powis, G ^a   Alberts, D S ^a  

^a UNIVERSITY OF ARIZONA   (United States)

Author keywords

chemoprevention; growth factors; intracellular signalling; oncogenes

Indexed keywords

ACETYLSALICYLIC ACID; ALPHA TOCOPHEROL; AMLODIPINE; ANTINEOPLASTIC AGENT; BRYOSTATIN 1; CARBACHOL; DILTIAZEM; EDELFOSINE; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; GROWTH FACTOR; NONSTEROID ANTIINFLAMMATORY AGENT; PROTEIN KINASE INHIBITOR; RETINOIC ACID; RETINOID; TAMOXIFEN; VERAPAMIL;

CANCER; CHEMOPROPHYLAXIS; HUMAN; PRIORITY JOURNAL; REVIEW; SIGNAL TRANSDUCTION;

ANIMAL; ANTICARCINOGENIC AGENTS; CALCIUM; HUMAN; NEOPLASMS; PHOSPHOLIPASE C; PROTEIN KINASE C; SIGNAL TRANSDUCTION; SUPPORT, U.S. GOV'T, P.H.S.;

EID: 0027981240     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/0959-8049(94)90473-1     Document Type: Article

References (128)

1. Chemoprevention of bladder cancer
2. Breast cancer chemoprevention
3. Prediction of human toxicity of new antineoplastic drugs from studies in animals
4. Signalling pathways as targets for anticancer drug development.
5. Signalling targets for anticancer drug development
6. q
7. q class of G proteins
8. 11 proteins in transfected Cos-7 cells
9. Inositol phosphates and cell signalling
10. The role of protein kinase C in transmembrane signalling
11. Control of transcription factors by signal transduction pathways: the beginning of the end
12. Phospholipases C and D in mitogenic signal transduction
13. EGF increases sn-1,2-diglyceride levels and activates phospholipase D-catalysed phosphatidylcholine breakdown in Swiss 3T3 cells in the absence of inositol lipid hydrolysis
14. Lysophosphatidic acid: a bioactive phospholipid with growth factor-like properties
15. Ligand-induced dimerization of the platelet-derived growth factor receptor
16. Platelet-derived growth factor stimulates tyrosine specific protein kinase activity in Swiss mouse 3T3 cell membranes
17. Protein with SH2 domains: transducers in the tyrosine kinase signalling pathway
18. Platelet-derived growth factor induces rapid and sustained tyrosine phosphorylation of phospholipase C-γ in quiescence BALB/c 3T3 cells
19. Phosphoinositide 3-kinase: a new effector in signal transduction?
20. Association of Sos Ras exchange protein with Grb2 is implicated in tyrosine kinase signal transduction and transformation
21. Identification of murine homologues of the Drosophila Son of sevenless gene: potential activation of ras
22. Epidermal growth factor regulates p21ras through the formation of a complex of receptor, Grb2 adapter protein, and Sos nucleotide exchange factor
23. The primary structure of MEK, a protein kinase that phosphorylates the ERK gene product
24. MAP kinase by any other name smells just as sweet
25. Raf-1 activates MAP kinase-kinase
26. Complexes of ras-GTP with raf-1 and mitogen-activated protein kinase kinase
27. ras mediates nerve growth factor receptor modulation of three signal transducing protein kinases: Map kinase, Raf-1 and RSK
28. Protein kinase C isoenzymes: divergence in signal transduction?
29. Pro-Leu-Ser/Thr-Pro is a consensus primary sequence for substrate protein phosphorylation. Characterization of the phosphorylation of c-myc and c-jun proteins by an epidermal growth factor receptor threonine 669 protein kinase
30. Identification of intracellular receptor proteins for activated protein kinase C
31. Selective translocation of β protein kinase C to the nucleus of human promyelocytic (HL60) leukemia cells
32. The protein kinase C-related PKC-L(eta) gene product is localized in the cell nucleus
33. c-myc gene induced alterations in protein kinase C expression: a possible mechanism facilitating myc-ras gene complementation
34. Transformation by a ras oncogene causes increased expression of protein kinase C-alpha and decreased expression of protein kinase C-epsilon
35. Overproduction of protein kinase C causes disordered growth control in rat fibroblasts
36. Altered growth regulation and enhanced tumorigenicity of NIH 3T3 fibroblasts transfected with protein kinase C-1 cDNA
37. Overexpression of protein kinase C-δ and -ϵ in NIH 3T3 cells induces opposite effects on growth, morphology, anchorage dependence, and tumorigenicity
38. The role of tamoxifin in the prevention and treatment of benign and malignant breast lesions: a chemopreventive
39. Establishment and characterization of UM-EC-2, a tamoxifen-sensitive, estrogen receptor-negative human endometrial carcinoma cell line
40. Effect of tamoxifen on DNA synthesis and proliferation of human malignant glioma lines in vitro
41. Antiproliferative effects on keratinocytes of a range of clinically used drugs with calmodulin antagonist activity
42. Specific and direct binding of protein kinase C to an immobilized tamoxifen analogue
43. Nonsteroidal antiestrogen suppresses protein kinase C—its inhibitory effect on interaction of substrate protein with membrane
44. Tamoxifen supresses tumor promoter-induced hydrogen peroxide formation by human neutrophils
45. The roles of calmodulin and protein kinase C in histamine secretion from mast cells
46. Evidence for a role for protein kinase C in the modulation of bombesin-activated cellular signalling in human breast cancer cells
47. Retinoids in cancer treatment
48. Characterization of cystolic calcium-activated phospholipid-dependent protein kinase activity in embryonal carcinoma cells
49. Induction of protein Kinase C in mouse melanoma cells by retinoic acid
50. Immunochemical evidence that three protein kinase C isozymes increase in abundance during HL-60 differentiation induced by dimethyl sulfoxide and retinoic acid
51. Effect of retinoic acid on cyclic AMP-dependent and calcium, phospholipid-dependent protein kinase activities: Counteraction to phorbol ester tumor promoter
52. 2+-activated, phospholipid-dependent protein kinase
53. A role for retinoids and a tumorpromoting phorbol ester in the control of protein phosphorylation
54. The inhibitory effect of a third generation retinoid, R8605, on protein kinase C activity in vitro
55. Purification of phosphatidylinositol synthetase from rat brain by CDP-diacylglycerol affinity chromatography and properties of the purified enzyme
56. A phase I study of intravenous bryostatin 1 in patients with advanced cancer
57. Regression of oral leukoplakia with alpha tocopherol: a community clinical oncology program chemoprevention study
58. Inhibition of smooth muscle cell proliferation and protein kinase C activity by tocopherols and tocotrienols
59. d-α-Tocopherol inhibits low density lipoprotein induced proliferation and protein kinase C activity in vascular smooth muscle cells
60. Inhibition of NF-κB DNA binding activity by α-tocopheryl succinate
61. Ether lipids in experimental cancer chemotherapy
62. Ether lipids in the therapy of cancer
63. Inhibition of protein kinase C, (sodium plus potassium)-activated adenosine triphosphatase, and sodium pump by synthetic phospholipid analogues
64. 2+ dependent protein phosphorylation system in various types of leukemic cells from human patients and in human leukemic cell lines HL60 and K562, and its inhibition by alkyl-lysophospholipid
65. Synthesis and biological activity of novel quaternary ammonium derivatives of alkylglycerols as potent inhibitors of protein kinase C
66. Effects of thioether phospholipid BM 41.440 on protein kinase C and phorbol ester-induced differentiation of human leukemia HL60 and KG-1 cells
67. Inhibition of protein kinase C by ether-linked lipids is not correlated with their antineoplastic activity on WEHI-3B and R6X-B15 cells
68. Synthesis of quaternary amine ether lipids and evaluation of neoplastic cell growth inhibitory properties
69. Inhibition of Na, K-ATPase and sodium pump by protein kinase C regulators sphingosine, lysophosphatidylcholine, and oleic acid
70. Selective inhibition of phosphatidylinositol phospholipase C by cytotoxic ether lipid analogues
71. Inhibition of the signalling enzyme phosphatidylinositol-3-kinase by antitumor ether lipid analogues
72. 3
73. Treatment of non-small cell lung cancer with the alkyllysophospholipid edelfosine—intermediate data analysis
74. Synthetic alkylphospholipid analogs; a new class of antitumor antigens
75. Modulation of chemical carcinogenesis in rats by alkyl lysophospholipids
76. Suppression of malignancy targeting cyclic AMP signal transducing proteins
77. Retinoic acid increases cyclic AMP dependent protein kinase activity in murine melanoma cells
78. Role of retinoids in differentiation and carcinogenesis
79. Tyrosine-phosphorylated proteins: mediators of signal transduction from the tyrosine kinases
80. Protein-tyrosine kinase inhibitors
81. Combination of blocking agents and suppressing agents in cancer prevention
82. Reduced tyrosine phosphorylation in polyamine-starved cells
83. Receptor-regulated calcium entry
84. Inhibition of cancer cell growth by calcium channel antagonists in the athymic mouse
85. A novel antiproliferative and antimetastasis agent which interferes with calcium signal transduction
86. L651582: a novel antiproliferative and antimetastasis agent
87. In vivo efficacy of a novel inhibitor of selected signal transduction pathways including calcium, arachidonate, and inositol phosphates
88. The antiproliferative and antimetastatic compound L651582 inhibits muscarinic acetylcholine receptor-stimulated calcium influx and arachidonic acid release
89. The inhibition of receptor-mediated and voltage-dependent calcium entry by the antiproliferative L-651, 582
90. Anti-proliferative activity of L-651, 582 correlates with calcium-mediated regulation of nucleotide metabolism at phosphoribosyl pyrophosphate synthetase
91. Calcium-mediated signal transduction: biology, biochemistry and therapy
92. Calcium antagonism by the antioestrogen tamoxifen
93. 2+ exchange of brain cortex membranes
94. Calcium channel antagonist properties of the antineoplastic antiestrogen tamoxifen in the PC12 neurosecretory cell line
95. Presence of transforming growth factors in human breast cancer cells
96. Effect of tamoxifen on carbachol-triggered intracellular calcium responses in chicken granulosa cells
97. 2+-dependent binding of tamoxifen to calmodulin isolated from bovine brain
98. Antagonistic effect of triphenylethylenic antiestrogens on the association of estrogen receptor to calmodulin
99. Variation of the inhibition of calmodulin dependent cyclic AMP phosphodiesterase amongst analogues of tamoxifen; correlations with cytotoxicity
100. Tamoxifen is a calmodulin antagonist in the activation of cAMP phosphodiesterase
101. The pharmacology and clinical uses of tamoxifen
102. A comparison of two doses of tamoxifen (Nolvadex) in postmentrual women with advanced breast cancer: 10 mg bd versus 20 mg bd
103. Ras genes
104. Ras C-terminal processing enzymes—new drug targets?
105. Chemoprevention of mammary carcinogenesis by hydroxylated derivatives of d-limonene
106. Selective inhibition of isoprenylation of 21–26-kDa proteins by the anticarcinogen d-limonene and its metabolites
107. Limonen-induced regression of mammary carcinomas
108. Limonene, inhibitor of ras-farnesylation, in the treatment of mammary tumours and phase I study in patients with cancer
109. The effects of bombesin on polyphosphoinositide and calcium metabolism in Swiss 3T3 cells
110. 2+ in quiescent 3T3 cells stimulated by platelet-derived growth factor, bom-besin and vasopressin
111. q protein induces malignant transformation in NIH 3T3 cells
112. Muscarinic acetylcholine receptor subtypes as agonist dependent oncogenes
113. Oncogenic forms of the neu/HER2 tyrosine kinqase are permanently coupled to phospholipase C-γ
114. Phospholipase C-γ1 and phosphatidylinositol 3 kinase are the downstream mediators of the PDGF receptor's mitogenic signal
115. Use of hepatic cell cultures to detect and evaluate the mechanism of action of toxic chemicals
116. Specific expression of phospholipase C-γ in human gial tumors
117. Increased phospholipase C(PLC)-γ, activity in human non-small cell lung (NSCLC) and renal cell (RCC) carcinomas correlates with elevated EGF receptor levels
118. 2+ signallingby antitumor ether lipid analogues
119. Hexadecylphosphocholine inhibits inositol phosphate formation and protein kinase C activity
120. Inhibition of phospholipase Cδ by hexadecylphosphorylcholine and lysophospholipids with antitumor activity
121. Inhibition of phospholipqase C and cell growth by ethr lipid analogues of phosphatidylinositol
122. 1 membranes
123. 2)
124. 2 activities by the triphenylethylene antiestrogen, tamoxifen, in immature quail oviduct
125. The differentiating agent, retinoic acid, causes an early inhibition of inositol lipid-specific phospholipase C activity in HL-60 cells
126. Risk factors for fatal colon cancer in a large prospective study
127. Aspirin inhibits phospholipase C